What is Implanet?
Founded in 2007, IMPLANET is dedicated to manufacturing high-quality implants for orthopedic surgery. The company's product portfolio is segmented into two primary ranges: innovative solutions for spinal pathologies, including the JAZZ® and OSD systems, and the MADISON implant for primary knee replacement surgery. IMPLANET's established orthopedic platform is distinguished by its product traceability and is protected by four international patent families. The JAZZ® system has achieved significant regulatory milestones, including 510(k) clearance from the U.S. Food and Drug Administration (FDA), CE mark approval in Europe, and ANVISA approval in Brazil. As of 2020, IMPLANET employed 29 staff and reported sales of 6.0 million.
How much funding has Implanet raised?
Implanet has raised a total of $2.1M across 1 funding round:
Debt
$2.1M
Debt (2024): $2.1M with participation from SPD Silicon Valley Bank
Key Investors in Implanet
SPD Silicon Valley Bank
SPD Silicon Valley Bank (SSVB) is a joint venture between Shanghai Pudong Development Bank and Silicon Valley Bank, focusing on providing financial products and services to the technology and innovation industry in China. They aim to support companies in sectors such as hardware, software, internet, mobile, consumer technology, life science, biotechnology, and cleantech.
What's next for Implanet?
With a major strategic investment now part of its financial structure, Implanet is poised for its next phase of growth. The company's established product lines, particularly the FDA-approved JAZZ® system for spinal conditions and the MADISON implant for knee surgery, provide a solid foundation. This recent capital infusion is likely to accelerate product development, enhance manufacturing capabilities, or expand its global distribution network. The company's focus on patented technology and regulatory approvals positions it for continued advancement in the orthopedic implant market.
See full Implanet company page
